Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiangzhiling is a Traditional Chinese Medicine (TCM) formulation, typically administered as granules or tablets, primarily used for the treatment of hyperlipidemia and the regulation of lipid metabolism. The formulation generally consists of several herbal ingredients, including *Polygonum multiflorum* (He Shou Wu), *Crataegus pinnatifida* (Shan Zha), and *Cassia obtusifolia* (Jue Ming Zi). In clinical research, specifically at Guangzhou Eighth People's Hospital, Jiangzhiling granules have been evaluated for their efficacy and safety in treating abnormal lipid metabolism (dyslipidemia) in HIV-infected patients undergoing Highly Active Antiretroviral Therapy (HAART). The treatment aims to mitigate metabolic side effects associated with long-term antiviral therapy and improve the overall cardiovascular health of patients through a combination of Chinese and Western medical approaches.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jiangzhiling.